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A child with perinatal HIV infection and long-term
sustained virological control following antiretroviral
treatment cessation
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Understanding HIV remission in rare individuals who initiated antiretroviral therapy (ART)
soon after infection and then discontinued, may inform HIV cure interventions. Here we
describe features of virus and host of a perinatally HIV-1 infected child with long-term
sustained virological control. The child received early limited ART in the Children with HIV
Early antiRetroviral therapy (CHER) trial. At age 9.5 years, diagnostic tests for HIV are
negative and the child has characteristics similar to uninfected children that include a high
CD4:CD8 ratio, low T cell activation and low CCR5 expression. Virus persistence (HIV-1 DNA
and plasma RNA) is conﬁrmed with sensitive methods, but replication-competent virus is not
detected. The child has weak HIV-speciﬁc antibody and T cell responses. Furthermore, we
determine his HLA and KIR genotypes. This case aids in understanding post-treatment control
and may help design of future intervention strategies.
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Rapid formation of persistent viral reservoirs follows acuteHIV-1 infection. This early establishment of latently HIV-1-infected CD4+ T cells harbouring replication-competent
virus remains the major obstacle to HIV cure or remission1–3. As
antiretroviral therapy (ART), even when given within days of
infection, usually fails to clear these reservoirs4–6, it is unlikely
that ART alone can lead to HIV remission. It is, however,
hypothesized that ART given very soon after infection may enable
a more effective immune response and, together with other
strategies, lead to sustained control of viral replication.
Current approaches to HIV cure or remission have focused on
either reversing latency (e.g. “shock and kill”), enhancing immune
responses or preventing immune activation (e.g. vaccines and
other immunotherapies)7. Central to the question of HIV
remission is the interaction between viral reservoir, immune
activation, host genetics and immune response.
Several adult cases of post-treatment control have been
described8–16. These individuals are unlike elite controllers (<1%)
who control HIV-1 to undetectable levels in the absence of
ART17,18, probably through distinct immunological
mechanisms8.
In children, data are extremely limited. In 2013, the report of
the “Mississippi baby” suggested that very early ART, here within
30 h of birth, could lead to prolonged (27 months) virological
control off-treatment19,20, raising hope for a feasible HIV-1
remission strategy. Unfortunately, this girl “relapsed” after almost
2 years without ART due to return of high levels of viral repli-
cation, and required ART. Subsequently, a French girl was
reported who started ART at 3 months of age, stopped treatment
between 5 and 7 years of age and controlled virus to undetectable
levels for over 12 years21.
Reports of post-treatment controllers who initiated ART and
then discontinued by design or unintentionally may help our
understanding of key host determinants of HIV replication
control, and inform interventions for HIV remission and cure.
Here we report a detailed virological and immunological ana-
lysis of a child at 9.5 years of age, originally enroled in the Chil-
dren with HIV Early antiRetroviral therapy (CHER) trial22,23 who
was randomized to the immediate, time-limited 40 weeks of ART
study arm. The CHER trial was initiated at a time when the best
strategy on when to initiate and how to maintain treatment in
infants was unclear. This child, one of 227 early treated children
(0.4%), is the only one maintaining long-term sustained vir-
ological control post-ART cessation. At 9.5 years, virus persists at
low levels (plasma RNA 6.6 copies per mL), cell-associated DNA
is 5 copies per million peripheral blood mononuclear cells and
replication-competent virus is not detected. Immunologically, he
is not unlike healthy children of similar age, evidenced by high
CD4:CD8 ratio, low T cell activation and low CCR5 expression.
He has weak HIV-speciﬁc antibody and CD4+ T cell responses
indicating memory of prior/current virus encounter, and together
with possession of some host genotypes, these provide clues for
future studies to inform what constitutes long-term post-treat-
ment control.
Results
Clinical case. The child, born in 2007, had a positive HIV-1 DNA
PCR at age 32 days. At 39 days, HIV-1 RNA was >750,000 copies
per mL (upper limit of quantitation of the assay) conﬁrming
infection; at 60 days, plasma HIV RNA had declined to 151,000
copies per mL. He commenced zidovudine, lamivudine and
lopinavir-ritonavir one day later (Fig. 1, Supplementary Table 1).
He was born at term, of normal birth weight (3700g), did not
receive nevirapine prophylaxis, and was not breastfed. CD4+ T
cell count and per cent at 61 days, prior to ART start, were 2249
cells per µL and 41.6%. These values fell within the respective
baseline interquartile ranges (IQRs) for all early treated children
who stopped ART in the CHER trial (Supplementary Table 2)—
n= 227 children; median CD4+ T cell count was 2255 (IQR:
1759–2972); median CD4% 36.4 (IQR: 31.4–42.5).
Viral load (VL) declined to <50 RNA copies per mL after
24 weeks of ART. At 50 weeks of age, when treatment was
stopped per trial protocol, VL was <20 copies per mL. Thereafter,
VL remained below detection over 8.75 years without ART
(Fig. 1a). CD4+ T cell counts remained normal-for-age (Fig. 1b)
and CD4% remained above 30% throughout (Fig. 1c). At 9.5
years plasma drug concentrations for the most commonly used
antiretroviral agents in South Africa were undetectable. The
mother’s CD4+ T cell count was 108 cells per µL when he was
7 months of age, and then 129 cells per µL 20 months later—these
are the only maternal data available.
Virus persistence. At 9.5 years, the Roche VL result was reported
as target not detected (TND; Fig. 2a). Virus pelleted from 10mL
of plasma, yielded 66 copies and a VL of 6.6 RNA copies per mL
(Fig. 2a). Using a highly sensitive RNA nested qPCR on 3mL of
plasma, 2 of 22 replicates were positive (Fig. 2a). Using a semi-
nested real-time PCR (sn-qPCR) assay and an input of 1 µg of
genomic DNA (gDNA) per well, total cell-associated HIV-1 DNA
was estimated at 5 copies per 106 peripheral blood mononuclear
cells (PBMCs; six of nine ampliﬁcations positive) (Fig. 2b). In a
stored sample from ART interruption at 50 weeks of age, this was
almost identical (5 copies per 106 PBMCs: 1 of 3 ampliﬁcations
positive). DNA sequencing of gag from the 9.5 year sample
conﬁrmed infection with subtype C virus (Fig. 2c). Using two
virus outgrowth assays (primary CD8-depleted PBMCs and
MOLT4/CCR5 cells), no replication-competent virus was detec-
ted at 9.5 years (Fig. 2d). However, a weak HIV RNA signal (1 of
24 replicates was positive) was detected in the day 28 supernatant
of cultured primary CD4+ cells from the 50-week sample using
qualitative real-time PCR nested assay (n-qPCR). The child’s
CD4+ T cells could be infected in vitro with the HIV-1 BaL strain
(Fig. 2d).
HIV-speciﬁc antibodies. At 9.5 years of age, HIV-speciﬁc anti-
bodies were undetectable by enzyme-linked immunosorbent
assay (ELISA) (optical density (OD) 0.056; cut-off 0.263), and the
western blot was indeterminate with weak reactivity to Gag
proteins (p24++, p40++ and p55/51+) (Fig. 3a). By multiplex
bead arrays the child showed a substantial IgA2 response to gp41,
and weak but detectable responses to gp120 and Vpu (IgG1), Gag
(IgG2), Tat (IgG2, IgG3, IgA1) and Vpu9 peptide (IgM) (Fig. 3b).
Cellular immune responses. The child possessed strong T cell
responses to staphylococcal enterotoxin B (SEB; 9.03% CD4,
6.35% CD8) and a very strong anti-CD16-induced natural killer
(NK) cell response (27.79% interleukin-2/interferon-γ (IL-2/IFN-
γ)+CD3−CD56+ cells) (Fig. 3c). A weak (0.116%) CD4+ T cell
response to Gag was detected, without detectable CD8+ T cell
responses to any peptide pool (Fig. 3d).
Host genotyping. All HLA loci were heterozygous: A*30:02:01/
66:01; B*08:01:01/44:03:01; C*04:01:01/07:01:01; DPB1*01:01:01/
18:01; DQB1*05:01:01/06:09:01; DRB1*12:01:01/13:02:01
(Fig. 4a). The child’s KIRAA1 genotype, the most common gen-
otype globally, included both full-length (f) and truncated (v)
KIR2DS4 alleles (Fig. 4b). These are among features that we have
associated with greater risk of transmission/acquisition of HIV-1
infection in mother-to-child transmission studies24,25. HLA
B*44:03:01 has a threonine (T) at position 80 as part of the Bw4
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epitope (NLRTALR) of the α1 helix 2 of the molecule—and
therefore will bind to KIR3DL1 on NK cells. HLA- Cw*07:01:01
(allotype C1) and Cw*04:01:01 (C2) have a lysine (K) and
asparagine (N) at position 80, respectively—allowing for inter-
action with both KIR2DL3 (C1) and 2DL1 (C2) on NK cells.
Collectively, these genotyping data suggest the potential for
diverse interactions that may include engagement of CD4 and
CD8 T cells and NK cells in antiviral responses.
Immunophenotyping. The CD4:CD8 T cell ratio was 1.9, higher
than all uninfected control children (Fig. 5a). Measurement of T
cell subsets representing various stages of differentiation
highlighted that 9.5–10-year-old HIV-uninfected children do not
display adult-like proportions of the different subsets, particularly
for naive, central memory and effector memory CD4+ T cell
subsets and central memory CD8+ T cells (Fig. 5b). The child
had high proportions of naive, central memory and effector
memory CD8+ T cells compared to uninfected children.
CCR5 density on CD4+ and CD8+ T cells was similar for
children and adults, with the child having lower CCR5 expression
than 14 of the 15 uninfected children/adults (Fig. 5c). Proportions
of the child’s CCR5-expressing CD4+ and CD8+ T cells were
comparable to those of uninfected children. Of note, CCR5-
expressing CD8+ T cells were signiﬁcantly higher in adults than
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Fig. 1 Longitudinal viral loads and CD4+ T cell counts. a–c Viral load (log10 RNA copies per mL) (a), absolute CD4+ T cell count (cells per µL) (b) and CD4
+ T cell percentage (c) are shown over time up to age 9.5 years (open circles joined by red dotted lines). Pre-ART, early ART and post-ART periods are
indicated (shaded in lavender, pink, pale green, respectively). The X-axis shows age in weeks and then in years, separated by a blue vertical dotted line.
Note: the detection limit of the VL assays used was 400 RNA copies per mL at 10.71 and 116.71 weeks; 50 RNA copies per mL at 33.71 weeks and 20 RNA
copies per mL at all other time points. ART antiretroviral therapy
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children (p= 0.0013; Mann–Whitney U test). Levels of immune
activation, measured by HLA-DR, were similar to those of
uninfected children and adults. Expression of TIGIT in the child’s
CD4+ and CD8+ T cells was similar to uninfected children, and
signiﬁcantly higher in adults (p= 0.027 and p= 0.0027, respec-
tively; Mann–Whitney U tests). PD-1 expression on the child’s
CD4+ T cells was substantially above the median values for
children or adults. However, two adult outliers had similarly high
levels. Similar to TIGIT, PD-1 expression on CD8+ T cells was
signiﬁcantly higher in adults than in children (p= 0.0007;
Mann–Whitney U test), with the child having high levels similar
to the adult median. Flow cytometry data are provided in
Supplementary Table 3.
Discussion
We report virological and immunological characteristics in a
South African child of 9.5 years of age in long-term HIV
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remission. He initiated ART at 8.7 weeks of age and discontinued
ART after 40 weeks in accordance to his randomization in the
CHER trial22. This is the only child to achieve this outcome
among 227 who stopped ART (at 40 or 96 weeks) in the trial
(0.4%). The French case of long-term remission was one of
15 children in the French paediatric cohort who stopped ART
(6.7%)21.
Studies have shown that earlier ART initiation results in a
smaller HIV reservoir size26–28. Treatment was very early (within
30 h of birth) for the Mississippi baby who achieved 27 months of
virological control off-treatment before experiencing virological
rebound19,20. This delay in rebound may have been attributed to
a small size of latent replication-competent reservoir. Both the
French case with >12 years of remission21 and this South African
case started ART later, at 3 and 2 months, respectively. HIV
transmission was likely intrapartum in the French child and in
utero in the Mississippi baby. The timing is unknown for the
South African child. Timing of transmission may have been a key
factor affecting the different outcomes of remission. Of note,
subtype of virus (B, H and C, respectively), treatment duration
(18 months, 6 years, 10 months, respectively) and ethnicity were
different in these children. Both earlier cases were girls, while this
is the ﬁrst report of a boy with HIV remission. Unlike the South
African child, using similar methods and number of CD4+
T cells, replication-competent virus was readily found in the
French case21. In contrast, no replication-competent virus was
found in the Mississippi baby when testing 22 million CD4+
T cells19, highlighting that this measure poorly predicts long-term
likelihood of remission. Furthermore, recent reports of very early
treatment in adult cases (within 2 weeks of infection) described
multiple sensitive tests for HIV-1 persistence, which supported
the absence of detectable virus during ART—these cases all
rebounded shortly after ART was stopped (n= 8 patients5;
median 26 days, range 13–48 days; n= 1 patient6, 225 days).
Collectively, these ﬁndings suggest some limited viral replication
may in fact be required for durable long-term remission.
Early in infection the child’s VLs were high, indicative of a highly
replicating virus. The VL declined from >750,000 to 150,000 RNA
copies per mL prior to beginning treatment, suggesting an immune
response attempting to control virus replication. After ART initia-
tion, viral decline was biphasic, with the expected initial sharp
decline followed by a more gradual decline. After ART cessation,
VLs remained below the detection threshold for 8.75 years.
More sensitive methods for VL measurement conﬁrmed the
presence of low amounts of virus produced in vivo (6.6 RNA
copies per mL). Inability to detect replication-competent virus
in vitro may be because of assay sensitivity (2 million CD4+ cells
tested), or defective virus that cannot accumulate to detectable
levels.
Early initiation of ART is associated with non-reactive
HIV antibody results in many HIV-1-infected children and
adults29–31. On standard assays the child is seronegative; however,
results from bead arrays revealed footprints of historical adaptive
responses that have either waned or are being maintained
through ongoing antigenic priming. The substantial IgA2
(mucosal) response to gp41 could be primed by microbial anti-
gens sharing homology with gp4132–34. However, a recent study
reported stronger gp41-speciﬁc IgA responses in elite controllers,
which could not be well explained by responses to microbial
antigens35. HIV-1 Env- and Vpu-speciﬁc NK cell antibody-
dependent cellular cytotoxicity (ADCC) responses, including
against C-terminal peptide Vpu19 (our Vpu9 peptide), are
associated with elite HIV-1 control36. Using a whole blood assay,
we have shown similar responses associated with reduced
maternal–infant HIV-1 transmission and lower VLs in HIV-1-
infected mothers37,38. The child lacked a detectable NK cell
response to any HIV-1 peptide pool, likely due to very low levels
of antibodies that target Env and Vpu. The Vpu9-IgM antibody
response suggests a potential for interaction with complement.
Anti-Tat IgG responses have also been associated with natural
HIV-1 control and improved immune function in ART-treated
patients receiving Tat vaccine39–42. Interestingly, an African study
highlighted that persistent anti-Tat IgM in addition to IgG might
be protective against disease progression41.
An IgG2 antibody response to Gag has been associated with
CD4+ T cell response and long-term nonprogression43. The child
had both responses. The weak Gag-speciﬁc CD4+ T cell response
without a detectable CD8+ T cell response is intriguing. Such
responses are reported in HIV-exposed uninfected individuals
and some HIV-uninfected individuals, only when using sensitive
cultured ELISpot assays44. However, the opposite exists in
untreated HIV-1-infected infants where we readily demonstrated
Gag-speciﬁc CD8+, but not CD4+ HIV-speciﬁc T cell responses
in the ﬁrst few months of life—using the same whole blood
intracellular cytokine assay as for the present study45. Further-
more, there is an absence of sustained HIV-speciﬁc T cell
responses in early ART-treated HIV-1-infected children46. The
CD4+ Gag response demonstrated in the child seems remarkable
given early treatment and long duration of viral suppression. The
CD4+ T cell response may be maintained by small amounts of
virus (replication-competent or replication-defective) or Gag
protein produced in vivo. Lack of CD8+ T cell response suggests
that CD8+ T cells might not be currently involved in controlling
levels of viraemia, supporting the possibility that HIV may be
Fig. 2 Detection of HIV RNA, HIV DNA and replication-competent virus. a Viral load results at 9.5 years of age when testing the standard 1 mL of plasma
(target not detected (TND); left) vs. 10 mL (middle) by the standard Roche assay. A qualitative ultrasensitive RNA nested integrase PCR (IN-qPCR) assay
conducted on 3mL plasma; DNAse treated to ensure no contaminating cell-associated HIV-1 DNA (right). b Quantitation of the total HIV-1 DNA reservoir
using a semi-nested quantitative reverse transcription PCR (RT-qPCR) assay at 9.5 years. The standard curve (orange squares) shows plasmid copy
number controls (1–100,000 copies) on the x-axis and corresponding cycle threshold values on the y-axis. The case replicates are shown as blue squares.
Curves lower than the 100 (1 copy) plasmid control are counted as 1 copy. c A neighbour-joining phylogenetic tree constructed using the partial gag-PR
sequence (1414 bp HXB2 nt 903–2334; Gag aa39-501, PR aa 1–28). Reference subtypes A–D (in blue, black, purple and green, respectively) are included
and the tree is rooted on SIV chimpanzee sequence (Los Alamos HIV sequence database; https://www.hiv.lanl.gov). Accession numbers (e.g. AF067155)
of reference sequences are indicated in the ﬁgure. Numbers at the nodes indicate percentage bootstrap scores (n= 1000). The child’s (Case) gag
consensus sequence (see Supplementary Fig. 1) is indicated and clusters with subtype C sequences (purple). d The ability to reactivate virus from the
child’s CD4+ T cells was measured using two co-culture methods: donor CD8-depleted peripheral blood mononuclear cells (PBMCs) and MOLT4/CCR5
cells (top of panel). Included is the healthy HIV-1-uninfected donor (negative control) and an HIV-1-infected patient with high viral load, CD4+ T cell count
<200 cells per µL (positive control). The ability to infect CD4+ cells from the case with HIV-1 BaL (bottom of panel). Donor and MOLT4/CCR5 cells were
included as positive controls. The case was tested at the indicated times (age). The different sizes and shades of blue colour of the circles represent the
p24 concentration in culture supernatants; the actual pg mL−1 values appear within the circles (the colour key shows ranges of levels of p24 according to
shade of blue, with p24 levels increasing with increasing intensity of colour). *Indicates the time point at which a very weak signal was obtained by
ultrasensitive nested RNA IN-qPCR assay in the 50-week sample
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defective for further infection of permissive cells. In keeping with
this, we hypothesize the HIV-1 reservoir in the child may be
maintained through homeostatic, antigen-stimulated or integra-
tion site-dependent proliferation of CD4+ T cells harbouring
transcription/translation-competent but not necessarily
replication-competent HIV-1. These cellular proliferative
mechanisms present a challenge for HIV-1 eradication strate-
gies47. In contrast, the French case showed weak but broader
CD4+ and CD8+ T cell responses to Gag, Pol and Nef, and with
readily achievable viral proliferation in culture21.
These collective ﬁndings raise questions of whether cross-
reacting antigens might, in addition to small amounts of virus
production in vivo, contribute to maintaining some of these
memory responses—and, if such responses contributed to
remission in this child. Importantly, lack of detection does not
preclude having CD8+ T cell responses48, or other protective
responses such as ADCC/phagocytosis in the presence of
maternal/child antibody, that may have been active early in life
and possibly essential to the outcome of HIV-1 remission. The
rapid decline in VL over a month prior to ART initiation may be
of considerable importance in understanding the reasons behind
virological control in the child. ART may have protected an early
pre-ART antiviral response that may otherwise have been com-
promised by continued viral replication.
The child had no HLA class I alleles shown in adults to
associate with HIV-1 control49, except for heterozygosity at all
HLA loci that is considered advantageous50. In contrast, the
French case was homozygous at three loci, considered dis-
advantageous21. The child possesses HLA class II alleles already
associated with the robust mucosal CD4+ T cell responses in elite
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Fig. 3 HIV-speciﬁc responses and immune response capability of the case at 9.5 years of age. a Detection of HIV-speciﬁc antibodies at 9.5 years of age by
western blot. The case antibody proﬁle is compared with controls that are a high positive, low positive and HIV-negative. HIV proteins corresponding to
bands in the blots are shown in the left grey-shaded block; the case proﬁle was positive for the core proteins indicated in pink. b Quantitation of HIV-
speciﬁc antibodies by multiplex bead array for all isotypes and subclasses (indicated on the left side—IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2) against gp41,
Gag, RT, gp120, Nef, Tat, Vpu, peptide Vpu9 and V1V2 scaffold antigens (indicated at the top). Results are expressed as mean ﬂuorescence intensities
(MFI)), the colour key shows ranges of MFI according to colour intensity (the darker the more HIV-speciﬁc antibody detected). A result is considered
positive if above the cut-off (mean ± 3 SD) determined from eight adult uninfected controls. Vpu9 amino acid sequence: STMVDMGHLRLLDVNDL. c
Proportions of natural killer (NK) cells that respond to anti-CD16 antibody, and CD4+ and CD8+ T cells that respond to staphylococcal enterotoxin B
(SEB) in a whole blood intracellular cytokine (ICC) assay that measures induction of interferon-γ (IFN-γ) and interleukin-2 (IL-2). HIV-uninfected adult
reference values for comparison (n= 21; median % and range)—natural killer (NK) anti-CD16%: 37.92 (12–67.6), CD4 SEB%: 6.04 (0.25–11.91), CD8
SEB%: 5.82 (0.18–18.94). d A weak positive CD4+ T cell response to Gag (0.116%) in the absence of a detectable CD8+ T cell response to Gag (<0.1%;
0.023%). UN: addition of costimulatory antibodies anti-CD28 and anti-CD49d, no stimulation with peptides
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controllers (DQB1*06 and DRB1*13:02:01)51. DQB1*06 has also
been associated with IgA responses to V1V2 and increased risk of
acquisition in the RV144 HIV vaccine trial52. Possession of these
class II alleles may explain why the CD4+ Gag response remains
detectable at 9.5 years, despite the low-level antigenic exposure.
KIR genotyping revealed some features already associated with
greater risk of vertical transmission in mother-to-child HIV
transmission studies24,25.
The child had a healthy CD4:CD8 T cell ratio and levels of
immune activation similar to healthy uninfected children of
similar age. Robust T cell and NK cell responses to stimuli sug-
gested a good immune response capability. CCR5 density on
T cells was amongst the lowest when compared to HIV-
uninfected children or adults—a feature that may be advanta-
geous. Although the child’s PD-1-expressing CD4+ T cell pro-
portions were higher than children and adults, PD-1-expressing
CD8+ T cells were comparable to adults but much higher than
children. High PD-1 expression is unlikely from immune
exhaustion given no evidence of high immune activation in the
child unlike in chronic untreated and virologically suppressed
ART-treated HIV-1 infection53,54. In this regard TIGIT, another
marker of immune exhaustion, is not different from that in
uninfected children. Overall, these features show an immune
system that closely resembles that of an uninfected child of
similar age, making this child an ideal example of post-treatment
HIV-1 control.
The ability of this child to both control virus to levels below
detection on standard assays and to control immune activation
presents the best of both worlds; these features have been
described separately for elite controllers18,55, non-pathogenic
nonhuman primate Simian immunodeﬁciency virus infection and
long-term non-progressing children56,57. Events that may have
led to sufﬁcient silencing of virus replication will be explored by
whole-genome sequencing of virus/provirus. Further investiga-
tion will expand our understanding of how the immune system
controls HIV-1 replication with accompanying low immune
activation, and inform future strategies for ART interruption and
other interventions for HIV remission.
Methods
The case and study participants. In the CHER trial (ClinicalTrials.gov Identiﬁer:
NCT00102960; 2005–2011), HIV-1-infected treatment-naive, asymptomatic
infants aged ≤12 weeks with a CD4% ≥25% were randomized to early limited ART
for 40 (ART-40W; n= 143) or 96 (ART-96W; n= 143) weeks or to deferred ART
(n= 125)23. In the ART-40W group, 122 met criteria to stop ART, together with
105 in the ART-96W group. Re-initiation of ART was based on a CD4% decrease
to <20% and on clinical criteria23. By the trial end, median follow-up was 4.9 years
(IQR: 3.7–5.3). The child in this report was randomized to the ART-40W arm.
Follow-up after the trial continued as part of PEPFAR-supported routine health
services and later in an observational study58,59. CD4+ T cell counts were deter-
mined using the FACSCount System (BD Biosciences, San Jose, CA, USA).
Plasma HIV-1 RNA levels were quantitated retrospectively on stored samples
by Roche Ampliprep/COBAS® Taqman HIV-1 Test, v2.0 (Roche Molecular
Systems, Inc., Branchburg, NJ, USA) with a lower detection limit of 20 RNA copies
per mL (except for three time points where detection limits of assays used were 50
or 400 RNA copies per mL).
To gain further insight into speciﬁc characteristics of this case, detailed
virological, immunological and genetic studies were undertaken at 9.5 years of age.
Some viral studies were conducted on stored samples from 50 weeks of age at ART
interruption. The mother is deceased and no stored maternal samples are available
for study.
For comparisons of immune cell phenotypes, we included samples from ﬁve
healthy age-matched HIV-uninfected children (3 females, 2 males; median 9 years,
range 9.5–10 years) and 10 HIV-uninfected adults (5 females, 5 males; median age
44 years, range 35–55 years) from the same population.
Ethics statement. The CHER trial was approved by the Ethics Committees of the
University of the Witwatersrand and Stellenbosch University. Thereafter, the
Human Research Ethics Committee of the University of the Witwatersrand pro-
vided approval for all subsequent observational studies and investigations of the
Case. All participants provided written informed consent. For all minors, a parent
or guardian gave written informed consent and the child gave written assent. We
have complied with all ethical regulations.
Assays to detect HIV-1 DNA and RNA. An sn-qPCR assay targeting reverse
transcriptase (RT) was developed for subtype C proviral DNA quantitation based on
methods of Pasternak et al.60 and Kiselinova et al61, and described in Kuhn et al28.
The sn-RT-qPCR is a two-step PCR in which the ﬁrst round of ampliﬁcation was
carried out using conventional PCR and allowed to proceed for 15 cycles only and
the total product of the ﬁrst-round PCR was subsequently used in the second round
of PCR, a real-time hydrolysis probe-based PCR using a ﬂuorescently labelled
TaqMan probe, one primer identical to the forward primer used in the ﬁrst-round
PCR and a second reverse primer designed to bind “deeper” within the amplicon.
The second-round PCR was carried out for the standard cycle numbers used in real-
time PCR (40 cycles). The numbers of HIV-1 proviral DNA copies were determined
by using the standard curve method. To construct the standard curve, known copies
of linearized HIV-1 p8.MJ4 plasmid DNA were serially diluted and ampliﬁed in a
background of HIV-1-negative human gDNA (the same amount used in the
experimental wells) and subjected to the same cycling conditions. Sequences of
primers and probe are as follows: ﬁrst-round PCR, sn-RT-forward primer-1 5′-CAT
TTC TTT GGA TGG GGT ATG A-3′ and sn-RT-reverse primer-1 5′-CCT GTT
CTC TGC CAA TTC TAA TTC TGC-3′; second-round qPCR, forward primer
identical sn-RT-forward primer-1 above and sn-RT-reverse primer-2; 5′-TTG CCC
AGT TTA ATT TTC CCA CTA-3′; sn-RT-probe; 5′−6 FAM-AGC TGG ACT GTC
AAT GA-MGB-3′. gDNA was extracted using the QIAamp DNA Blood kit (Qiagen,
Hilden, Germany). Conventional PCR was performed using the Roche Expand
High-Fidelity (HiFi) PCR System (Roche Diagnostics GmbH, Roche Applied Sci-
ence, Mannheim, Germany) and the qPCR was carried out using LightCycler 480
Probes Master Mix (Roche Diagnostics). Cycling conditions were standard for both
Expand HiFi and TaqMan hydrolysis probe qPCR. At 9.5 years of age, a total of 9 µg
of gDNA extracted from isolated PBMCs (cell equivalent is 1.36 × 106 cells) was
tested at an input of 1 µg per well. The standard curves were run in triplicate at each
plasmid dilution, except for the 1 copy standard where ﬁve replicates were done. At
50 weeks of age, 3 µg of PBMC DNA (cell equivalent is 4.54 × 105 cells) was tested.
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Fig. 4 HLA class I and II alleles and KIR genotype. a HLA class I A, B and C with corresponding allotype designations (non-Bw4, Bw6, Bw4-80TA, C1 and
C2), and HLA class II DPB1, DQB1 and DRB1 alleles are indicated as allele 1 and 2. HLA B*44:03:01 has a threonine (T) at position 80 as part of the Bw4
epitope (NLRTALR) of the α1 helix 2 of the molecule—and therefore will bind to KIR3DL1 on NK cells. HLA- Cw*07:01:01 (allotype C1) and Cw*04:01:01
(C2) have a lysine (K) and asparagine (N) at position 80, respectively—allowing for interaction with both KIR2DL3 (C1) and 2DL1 (C2) on NK cells. b The
presence (coloured box) or absence of 16 KIR genes (14 functional and 2 pseudogenes 2DP1 and 3DP1) is shown. The child has an AA1 genotype, which has
9 KIR genes, has 2 copies of KIR3DL1 and 2 copies of activating gene KIR2DS4 with one full-length (f) and one truncated (v) version (heterozygous f/v). 2D:
2-domain; 3D: 3-domain; L: long tail, inhibitory; S: short tail, activating
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An in-house ultrasensitive n-qPCR, targeting the highly conserved integrase (IN)
gene designed using all subtype C sequences available on the Los Alamos HIV
Database (https://www.hiv.lanl.gov/), was used to detect subtype C HIV-1 DNA and
RNA. Brieﬂy, the n-qPCR assay is a two-step PCR with the ﬁrst PCR being a standard
PCR allowed to proceed to end-point (30 cycles) using the Roche Expand HiFi PCR
system and the second PCR a hydrolysis probe real-time PCR using Roche
LightCycler 480 Probes Master Mix. The total product generated in the ﬁrst-round
PCR is used in the second round. Negative controls include both water and gDNA or
RNA extracted from healthy HIV-1-uninfected donors. Positive controls include
gDNA/RNA extracted from known HIV-1-infected individuals. Sequences of primers
and probe are as follows, ﬁrst-round PCR: n-IN-forward primer-1 5′-TGG CAG TRT
TCA TTC ACA ATT TTA-3′; n-IN-reverse primer-1 5′-TCC TGT CYA CYT GCC
ACA CAA TCA-3′; second-round qPCR: n-IN-forward primer-2 5′-CGG GTT TAT
TAC AGR GAC AGC AGA G-3′; n-IN-reverse primer-2 5′-ACT ACT GCY CCT
TCA CCT TTC CA-3′; n-IN-probe 5′−6 FAM-TTG GCT GGT CCT TTC CA-
MGB-3′. gDNA was extracted using the QIAamp DNA Blood kit (Qiagen). RNA was
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Fig. 5 Immunophenotyping of CD4+ and CD8+ T cells. a–c Cell parameters determined by ﬂow cytometry for the child at 9.5 years are compared with
those of uninfected age-matched children (n= 5) and uninfected adults (n= 10): a CD4:CD8 ratio. b Percentages of CD4+ and CD8+ T cell subsets
according to stage of differentiation. Naive (CD45RO−CCR7+CD62L+CD95−); SCM: stem cell memory (CD45RO−CCR7+CD62L+CD95+); CM:
central memory (CD45RO+CCR7+CD62L+CD95+); TM: transitional memory (CD45RO+CCR7−CD62L+CD95+), EM: effector memory (CD45RO
+CCR7−CD62L−CD95+); TE: terminal effector (CD45RO−CCR7−CD62L−CD95+). c CCR5 density and percentages of cells expressing CCR5, HLA-DR
(immune activation), TIGIT and PD-1 (immune checkpoint inhibitory molecules) on CD4+ and CD8+ T cells. Uninfected children were compared to adults
using two-tailed non-parametric Mann–Whitney U tests; individual data points are shown as coloured circles; medians are shown as solid lines; statistical
signiﬁcance at P < 0.05 is indicated. One adult outlier (extreme) data point was omitted from the CD8+HLA-DR+ graph; the adult vs. children comparison
was not statistically different with or without this data point (P > 0.05)
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extracted from plasma or culture supernatant using the Qiagen QIAamp Viral RNA
kit. Complementary DNA was synthesized using the Invitrogen SuperScript III First-
Strand Synthesis System for RT-PCR (Thermo Fisher Scientiﬁc, MA, USA) and a
combination of a gene-speciﬁc primer (reverse primer-1) and random hexamers.
DNase treatment of extracted RNA was carried out using the Ambion TURBO DNA-
free kit (Thermo Fisher Scientiﬁc). Cycling conditions were standard for both Expand
HiFi and TaqMan hydrolysis probe qPCR.
HIV-1 proviral gag sequencing. The near full-length HIV-1 gag gene encom-
passing partial p17Gag coding regions to the Gag stop codon was PCR-ampliﬁed
from gDNA isolated from CD4+ T cells using an in-house nested PCR assay. A
ﬁrst-round PCR ampliﬁcation was performed using outer PCR primers gagoutF
(5′-TGT TAA AAC ACT TAG TAT GGG CAA G-3′) and gagoutR (5′-TTA CTT
TGA TAA AAC CTC CAA TTC C-3′) using the Roche FastStart HiFi PCR system
(Roche Diagnostics). A second-round PCR ampliﬁcation was performed using a
tenth volume of ﬁrst-round PCR product and second-round PCR primers gaginF
(5′-TTG CAC TTA ACC CTG GCC TTT TAG A) and gaginR (5′-ATT TAT TTC
TTC TAA TAC TGT ATC ATC TGC-3′). PCR products were puriﬁed using
Agencourt Ampure XP magnetic bead separation (Becton-Dickinson, Franklin
lakes, NJ, USA), cloned into pCR4-TOPO plasmid vectors (Invitrogen, Carlsbad,
CA, USA) and transformed into Escherichia coli bacteria. Plasmid inserts were
sequenced using BigDye Terminator v3.1 Cycle Sequencing Master Mix (Life
Technologies, Carlsbad, CA, USA) and eight sequence primers. The two inner PCR
primers and six overlapping internal sequencing primers (gagsegF1: 5′-GCT CTT
CAG ACA GGA ACA GA-3′, gagsegF2: 5′-GGA CAT CAA GCA GCC ATG C
A-3′; gagsegF3: 5′-GAA GAA ATG ATG ACA GCA TG-3′; gagsegR1: 5′-CCT GCT
ATG TCA CTT CCC CT-3′; gagsegR2: 5′-TTT CCA CAT TTC CAA CAG CC-3′;
gagsegR3: 5′-TTT CCA CAT TTC CAA CAG CC-3′) were used to generate gag
sequences. Sequence products were resolved on an ABI3100 PRISM Genetic
Analyser instrument (Life Technologies, Carlsbad, CA, USA). DNA sequences were
analysed using Sequencher v4.5 software (Gene Codes Corporation, Ann Arbor,
MI, USA). A consensus sequence (Supplementary Fig. 1) was derived from
sequencing multiple cloned gag fragments (Genbank accession numbers:
MH789553–MH789572), and viral subtype was determined by phylogenetic ana-
lysis with reference subtypes A–D using MEGA version 462.
Viral outgrowth assays. The presence of replication-competent virus was assessed
through two viral outgrowth assays with modiﬁcations63. CD4+ T cells isolated
from a stored sample of the case at 50 weeks of age (2 × 106 cells) and from a fresh
sample at 9.5 years (2 × 106 cells) were activated with phytohemagglutinin (PHA)
(5 µg mL−1) for 2 days in media supplemented with IL-2 (20IUmL−1; Roche
Diagnostics), washed and added to PHA-stimulated CD8-depleted PBMCs (4.0 ×
106 cells) from a healthy HIV-1-uninfected donor (with high CCR5 expression as
determined by ﬂow cytometry) or 3 × 105 MOLT4/CCR5 cells. Culture super-
natants were tested for HIV-1 p24 by ELISA (Alliance kit, Perkin Elmer Life
Sciences Inc., UK). For increased sensitivity, the n-qPCR was used to detect HIV-1
RNA in pooled and pelleted supernatant samples. MOLT4/CCR5 cells (Cat. No.
4984) were obtained through the NIH AIDS Reagent Programme, NAIAD, NIH
from Dr. Masanori Baba, Dr. Hiroshi Miyake and Dr. Yuji Iizawa64.
Infection of CD4 T cells in vitro. The child’s CD4+ T cells were tested for
permissiveness to infection by HIV-1 BaL. CD4+ T cells (1 × 106 cells) from the
child were activated with PHA (5 µg mL−1) in media supplemented with IL-2
(20 IU mL−1) for 2 days, and then inoculated with HIV-1 BaL (~10 ng p24; CCR5-
tropic virus; 2 h, 37 °C CO2 incubator). PHA-stimulated CD8-depleted PBMCs
from a healthy HIV-1-uninfected donor (high CCR5 expression) as well as 3 × 105
MOLT4/CCR5 cells infected with ~10 ng p24 HIV-1 BaL were included as positive
controls. Supernatants were harvested and quantitated by p24 ELISA. HIV-1 BaL
was from Dr. Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert Gallo65 (Cat.
No. 510, NIH AIDS Reagent Programme, Division of AIDS, NIAID, NIH).
Measurement of HIV-speciﬁc antibodies. The presence of HIV-1-speciﬁc anti-
bodies in plasma was determined by GS HIV-1 western Blot (Bio-Rad Laboratories,
Inc., USA), by ELISA (Genescreen Ultra Ag/Ab; Bio-Rad Laboratories) and a
microsphere-based array assay (Bio-Rad). HIV-1 antigens were covalently con-
jugated onto carboxylated magnetic ﬂuorescent beads (Bio-PlexTM Magnetic
COOH beads; 1.25 × 107 beads per mL; Bio-Rad) using a standard two-step car-
bodiimide coupling procedure (Luminex MAP® technology66). Brieﬂy, the stock
suspension of beads was vortexed at high speed to disperse bead aggregates and an
aliquot of beads (1.25 × 106) was transferred to a coupling reaction tube, washed
with dH2O and resuspended in activation buffer (0.1 M NaH2PO4, pH 6.2), fol-
lowed by the addition of 50 mgmL−1 of N-hydroxysulfosuccinimide (Pierce,
Rockford, IL, USA) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydro-
chloride (Sigma-Aldrich, St. Louis, MO, USA) and incubated for 20 min in the dark
at room temperature. Activated beads were washed with coupling buffer (50 mM
MES, pH 5.0) and resuspended with antigen (5–6.25 µg) to a ﬁnal volume of 500 µL
with 50 mM MES, pH 5.0, for 2 h, in the dark at room temperature. After incu-
bation, the beads were washed twice with storage/blocking buffer (PBS-TBN:
phosphate-buffered saline (PBS), 0.1% bovine serum albumin (BSA), 0.02%
Tween-20, 0.05% sodium azide), counted using a haemocytometer and stored in
the dark at 4 °C.
HIV-speciﬁc immunoglobulin isotypes were detected by preparing a microsphere
mixture comprising the seven HIV antigen-coupled beads (gp41, Gag, RT, gp120,
Nef, Tat, Vpu, peptide Vpu9 and V1V2 scaffold; Supplementary Table 4). To each
well of a 96-well ﬂat bottom Greiner plate (Bio-Rad), 50 µL of working microsphere
mixture prepared in assay buffer (PBS, 1% BSA; 2500 beads from each bead region
per well), 40 µL assay buffer and 25 µL of patient plasma (diluted 1:75 in assay buffer)
was added. Following an incubation period (on a shaker in the dark at room
temperature; 2 h), the plate was washed three times with wash buffer (PBS, 0.1%
BSA, 0.05% Tween-20) with a ﬁnal wash in assay buffer. HIV-speciﬁc antibody
isotypes were detected by adding 50 µL per well at 2 µgmL−1, R-phycoerthyrin-
conjugated mouse anti-human IgG1 to IgG4 (Cat. Nos 9052-09, 9070-09, 9210-09,
9200-09, respectively, Southern Biotech, USA), mouse anti-human IgM (Cat. No.
9020-09, Southern Biotech), mouse anti-human IgA1 (Cat. No. 9130-09, Southern
Biotech) or mouse anti-human IgA2 (Cat. No. 9140-09, Southern Biotech) with
shaking (in the dark at room temperature) followed by three washes. Beads were
ﬁnally resuspended in Bio-Rad sheath ﬂuid and analysed using the Bio-Plex 200
instrument (Bio-Rad) by measuring the ﬂuorescence signal for 50 beads per analyte.
Background signal, deﬁned as the mean ﬂuorescence intensity (MFI) for each
microsphere set when incubated with PE detection Ab in the absence of patient
plasma, is subtracted from the ﬂuorescent intensity of each sample. The cut-off for
seropositivity for each analyte is calculated as the average MFI value from pooled
plasma from HIV-1-uninfected patients plus 3 standard deviations. HIV-Ig (Cat. No.
3957; NIH AIDS Reagent Programme) served as a positive control on each plate and
the MFI values tracked with a Levy–Jennings plot.
Intracellular cytokine assays. HIV-1-speciﬁc T cell (CD4+, CD8+) and NK cell
responses were measured using a whole blood intracellular cytokine assay (IFN-γ
and IL-2) stimulated with overlapping HIV-1 subtype C synthetic peptides in pools
representing Gag, Pol, Nef, Env, Tat, Rev, Vif, Vpu and Vpr proteins. Brieﬂy, 200 µL
of whole blood, collected in sodium heparin, was stimulated with a ﬁnal con-
centration of 10 µgmL−1 of peptide (synthesized as 15–18 mers overlapping by 10
amino acids, with the exception of Nef, which overlaps by 11 amino acids, NMI,
Germany) together with 1 µg of the costimulatory antibodies CD28 and CD49d (Cat.
Nos 340975 and 340976, respectively, BD BioSciences) and the transport inhibitor
brefeldin A (10 µgmL−1; Sigma-Aldrich). Positive controls were stimulated with
1 µg/mL SEB (Cat. No. S4881, Sigma-Aldrich) for T cells or with 5 ngmL−1 anti-
CD16 antibody (Clone eBioCB16, Cat. No. 16-0168-85, eBioscience, San Diego, CA,
USA) for NK cells. The latter measures reverse ADCC, therefore providing a measure
of the capacity of NK cells to perform ADCC through engagement with FcγRIIIa/
CD16a receptors. To monitor spontaneous cytokine release, the equivalent amount
of dimethyl sulfoxide, as in the peptide tubes, together with the costimulatory
antibodies was prepared. Samples were incubated for 6 h at 37 °C, after which they
were maintained at 18 °C overnight. Twenty microlitres of ethylenediaminete-
traacetic acid (EDTA) was added for 15min, following which red blood cells were
lysed for 10min at room temperature using 2mL FACS lysing solution (BD Bios-
ciences). FACS permeabilizing solution (500 µL; 15min; room temperature; BD
Biosciences) was added to centrifuged samples which were washed twice before
staining with CD3 PerCP (clone SK7, Cat. No. 345766, 5 µL), CD8 FITC (clone SK1,
Cat. No. 347313, 5 µL), CD4 BV786 (clone L200, Cat. No. 563914, 0.8 µL), CD56
APC (clone NCAM16.2, Cat. No. 341025, 5 µL of a 1:16 dilution), IL-2 phycoery-
thrin (PE) (clone 5344.111, Cat. No. 340450, 10 µL) and IFN-γ PE (clone 25723.11,
Cat. No. 340452, 5 µL) for 60min at room temperature in the dark. Stained cells were
acquired using a 4-laser BD LSRFortessaTM X-20 ﬂow cytometer (BD Biosciences)
and analysed (gating strategy in Supplementary Fig. 2) using the FlowJo Software
(Tree Star Inc., Ashland, OR, USA).
Multiparameter ﬂow cytometry. Whole blood immunophenotyping by multi-
colour ﬂow cytometry (to determine proportions of naive/memory CD4+ and CD8
+ T cell subsets) included measures of CCR5 expression (density and %), immune
activation (HLA-DR) and immune exhaustion (TIGIT and PD-1). The following
antibodies were used, in three antibody panels: CD3 APC-H7 (clone SK7, Cat. No.
560176, 2 µL), CD8 PerCP (clone SK1, Cat. No. 347314, 6.5 µL), CD8 Alexa Fluor
700 (clone RPA-T8, Cat. No. 557945, 2 µL), CD4 BV786 (clone L200, Cat. No.
563914, 0.8 µL), CD4 FITC (clone SK3, Cat. No. 347413, 6 µL), CCR5 PE (clone
2D7, custom 1:1 conjugated antibody, 10 µL), CCR7 FITC (clone 150503, Cat. No.
150503, 6.5 µL), CD45RO BV510 (clone UCHL1, Cat. No. 563215, 4 µL), CD62L
PE-CF594 (clone DREG-56, 1.6 µL), PD-1 BV786 (clone EH12.1, 3.3 µL) were
obtained from BD Biosciences. TIGIT APC (MBSA43, Cat. No. 562301, 1.6 μL) was
obtained from eBioscience, HLA-DR PE-Cy5.5 (clone TU36, Cat. No. MHLDR18,
1.6 µL) was obtained from Life Technologies and CD95 BV605 (clone DX2, Cat.
No. 305628, 6.5 µL) was obtained from BioLegend (San Diego, CA, USA). The
CCR5 antibody was conjugated to PE at a ratio of 1:1, and quantitation (density
measured as antibodies bound per cell) was carried out using the QuantiBRITE
system (BD Biosciences). Whole blood (100 μL) was incubated with the antibodies
at room temperature, in the dark, for 15 min. Thereafter, red blood cells were lysed
using FACS lysing solution (BD Biosciences). Samples were then washed and
resuspended in FACSﬂow. Stained cells were acquired on a 4-laser BD LSRFor-
tessaTM X-20 ﬂow cytometer (BD Biosciences) and analysed (antibody panels and
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gating strategies in Supplementary Fig. 3-5) using the FlowJo Software (Tree Star
Inc.).
Host genotyping. HLA class I and II and KIR genotyping was conducted on gDNA
extracted from blood cells (QiaAmp DNA blood mini kit, Qiagen). The sequence-
based typing resolver kits (Conexio Genomics, Fremantle, Australia) were used to
generate HLA-A, HLA-B, HLA-C, DRB1, DPB1 and DQB1 amplicons for DNA
sequencing as described by the manufacturers. The exons included for DNA
sequencing are: exons 1–4 for HLA-A and HLA-B; exons 1–8 for HLA-C; exons 2
and 3 for HLA-DRB1 and HLA-DQB1; exons 1–5 for HLA-DPB1.
The presence or absence of the 16 KIR genes (14 functional and 2 pseudogenes
2DP1 and 3DP1) were determined using allele-speciﬁc (AS) primers
(Supplementary Table 5) in a real-time PCR assay67. Brieﬂy, PCR reactions were
performed in a 5 µL volume, containing 2× Maxima SYBR Green/ROX qPCR
Master Mix (Fermentas, Burlington, ON, Canada), 0.2 µM of KIR-speciﬁc primers,
0.2 µM of galactosylceramidase-speciﬁc primers and 5 ng of DNA. Thermocycling
was performed using the Applied Biosystems 7500 Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA) under the following conditions: 95 °C
for 10 min, followed by 30 cycles of 95 °C for 15 s and 60 °C for 1 min, with
subsequent melt-curve analysis.
Published primers and probe speciﬁc for KIR2DS4 full-length (f; *001) or
truncated (v; *003,004,006,007,009) alleles68 and KIR3DL1/S169 were used in
combination with the primers and probe speciﬁc for the human β-globin (BGB)
reference gene70 (Supplementary Table 6) in a probe hydrolysis-based relative
quantiﬁcation real-time allele-speciﬁc (AS)-PCR assay to determine gene copy
number variation (KIR2DS4 and KIR3DL1/3DS1). To facilitate target and reference
gene multiplexing, KIR-speciﬁc probes were labelled at the 5′ end with the
ﬂuorochrome VIC, while BGB probes were labelled with the ﬂuorochrome FAM.
Control samples of known gene copy numbers were run concurrently with
unknowns and gene copy numbers inferred using a delta Ct method (difference
between Ct values obtained for KIR and BGB genes). All samples were run in
duplicate. Real-time AS-PCR ampliﬁcation was performed in 96-microwell PCR
plates using an ABI7500 real-time PCR instrument (Life Technologies, Carlsbad,
CA, USA). Reaction volumes were 5 µL containing 5 ng of genomic DNA, 2×
LightCycler 480 Probes Master Mix (Roche), 0.5 µM KIR3DL1/S1 or KIR2DS4f/v
forward/reverse primers (Inqaba Biotec, Pretoria, RSA), 0.5 µM BGB forward/
reverse primers (Inqaba Biotec, Pretoria, RSA), 0.1 µM VIC-labelled KIR3DL1/S1
or KIR2DS4f/v probe and 0.1 µM FAM-labelled BGB probe (Life Technologies,
Carlsbad, CA, USA). Cycling conditions were an initial incubation of 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s, 55 °C for 10 s and 60 °C for 30 s.
Data availability
The data that support the ﬁndings in this study are available from the corre-
sponding authors upon reasonable request. The source data underlying Figs 1a–c
and 5a–c are provided in Supplementary Tables 1 and 3, respectively. Genbank
accession numbers for cloned gag proviral sequences: MH789553–MH789572.
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